BioCryst halts enrollment in all studies for its lead pipeline candidate — shares crash
BioCryst is taking a beating Friday morning after reporting it would pause enrollment in three studies for its lead pipeline program.
In a terse …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.